Renal care companies develop business through vertical integration and innovative home care products
This article was originally published in Clinica
Although dialysis technology has changed little over the years, companies are constantly developing new treatment techniques and solutions as the number of people suffering from end-stage renal disease (ESRD) continues to climb by an annual average of 8%. Some 800,000 people worldwide require dialysis treatment making a product market of about $6 billion with the cost of treatments worth approximately $23 billion, according to a new report published by Theta Reports, entitled Kidney dialysis equipment & supplies.
You may also be interested in...
Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.
However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.
In last year’s acquisition, Bristol Myers Squibb agreed to pay Celgene investors another $9 per share based on three approvals, including idecabtagene vicleucel (bb2121) by 30 March 2021.